Tìm theo
Teriparatide
bone density conservation agents
Thuốc Gốc
Biotech
CAS: 52232-67-4
ATC: H05AA02
ĐG : Eli Lilly & Co. , http://www.lilly.com
CTHH: C181H291N55O51S2
PTK: 4117.7150
Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C181H291N55O51S2
Phân tử khối
4117.7150
Dược Lực Học : Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Cơ Chế Tác Dụng : Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company. Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Dược Động Học :
▧ Absorption :
Bioavailability is 95% following subcutaneous injection.
▧ Volume of Distribution :
* 0.12 L/kg
▧ Metabolism :
Hepatic
▧ Route of Elimination :
Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%).
▧ Clearance :
* 62 L/hr [Women] * 94 L/hr [Men]
Độc Tính : Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Chỉ Định : For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Liều Lượng & Cách Dùng : Solution - Subcutaneous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06285
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D06078
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0002-8400-01
PharmGKB
http://www.pharmgkb.org/drug/PA451620
Wikipedia
http://en.wikipedia.org/wiki/Teriparatide
Drugs.com
http://www.drugs.com/cdi/teriparatide.html
... loading
... loading